-
公开(公告)号：US12083339B2
公开(公告)日：2024-09-10
申请号：US16340106
申请日：2017-10-06
Inventor： Jill W. Ivey , Eduardo L. Latouche , Scott S. Verbridge , Rafael V. Davalos , Glenn J. Lesser , Waldemar Debinski
CPC classification number: A61N1/327 , A61B18/12 , A61B18/1233 , A61K38/19 , A61N1/05 , A61N1/06 , A61B2017/00172 , A61B2018/00613 , A61B2018/00732 , A61B2018/00767 , A61B2018/126 , A61B2018/128 , A61K38/1793
Abstract: Described herein are methods of electroporation that can include the steps of contacting a cell that is responsive to an EphA2 receptor ligand with an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to the cell. Also described herein are methods of treating cancer in a subject in need thereof, wherein the methods can include the steps of administering an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to a location on or within the subject.
-
公开(公告)号：US11136367B2
公开(公告)日：2021-10-05
申请号：US16704645
申请日：2019-12-05
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Gibo
IPC: G01N33/532 , C07K14/54 , A61K47/64 , C07K14/34 , G01N33/50 , G01N33/68 , C07K14/21 , C07K19/00 , C07K14/005 , C07K14/195 , A61K38/00
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
-
3.发明授权公开(公告)号：US10233224B2
公开(公告)日：2019-03-19
申请号：US15695392
申请日：2017-09-05
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Gibo
IPC: C12N15/24 , C07K14/54 , C07K19/00 , C07K14/21 , C07K14/34 , G01N33/50 , G01N33/532 , G01N33/68 , C07K14/005 , C07K14/195 , A61K47/64 , A61K38/00
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
-
公开(公告)号：US20180244745A1
公开(公告)日：2018-08-30
申请号：US15958608
申请日：2018-04-20
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Carla Lema Tome , Sara Ferluga , Poonam S. Sonawane
IPC: C07K14/705 , C07K14/52 , C07K14/54 , G01N33/574
Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Ra2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
-
公开(公告)号：US09975942B2
公开(公告)日：2018-05-22
申请号：US15035560
申请日：2014-11-11
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Carla Lema Tome , Sara Ferluga , Poonam S. Sonawane
IPC: C07K14/705 , C07K14/52 , C07K14/54 , G01N33/574 , A61K38/00
CPC classification number: C07K14/705 , A61K38/00 , C07K14/52 , C07K14/5437 , C07K2319/01 , C07K2319/06 , C07K2319/09 , C07K2319/30 , C07K2319/33 , C07K2319/55 , C07K2319/74 , G01N33/57492
Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Rα2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
-
Patent Agency Ranking
公开(公告)号：US09868788B2
公开(公告)日：2018-01-16
申请号：US14776356
申请日：2014-03-14
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Denise Mazess Herpai
IPC: C07K16/28 , A61K47/48 , A61K49/00 , C12N9/00 , A61K39/395
CPC classification number: C07K16/2866 , A61K39/3955 , A61K47/6813 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6911 , A61K49/0004 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C12N9/93 , C12Y603/01004
Abstract: Provided herein is an antibody (e.g., an isolated antibody) that specifically binds an epitope (e.g., linear epitope) within amino acids spanning the extracellular portion of human IL-13RA2. In some embodiments, the amino acids spanning the extracellular portion of human IL-13RA2 have at least 90% identity with the corresponding canine sequence of IL-13RA2. In some embodiments, the antibody specifically binds both human and canine IL-13RA2. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a recombinant antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody is the monoclonal antibody produced by hybridoma 1E10B9 or a recombinant form thereof.
-
公开(公告)号：US20130164257A1
公开(公告)日：2013-06-27
申请号：US13718166
申请日：2012-12-18
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Gibo
IPC: C07K19/00
CPC classification number: C07K14/5437 , A61K38/00 , A61K47/642 , C07K14/005 , C07K14/195 , C07K14/21 , C07K14/34 , C07K19/00 , C07K2319/01 , C07K2319/09 , C07K2319/74 , G01N33/5008 , G01N33/5091 , G01N33/532 , G01N33/6869 , G01N2333/025 , G01N2333/195 , G01N2333/5437
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
Abstract translation: 化合物，其组合包含：细胞表面结合配体或内在因子，例如IL-13Rα2结合配体; 至少一个效应分子（例如，一个，两个，三个或更多个效应分子）; 任选但优选地，共价偶联在所述结合配体和所述至少一个效应分子之间的细胞质定位元件; 以及在所述结合配体和所述至少一个效应分子之间共价偶联的亚细胞区室定位信号元件（优选与所述结合配体和所述亚细胞定位信号元件之间的所述细胞质定位元件）。 还描述了使用这些化合物的方法和含有该化合物的制剂。
-
公开(公告)号：US20180243368A1
公开(公告)日：2018-08-30
申请号：US15957445
申请日：2018-04-19
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Jill Wykosky , Denise Mazess Herpai
CPC classification number: A61K38/177 , A61K38/00 , A61K38/2086 , A61K38/45 , A61K45/06 , A61K47/64 , A61K47/642 , A61K47/6801 , A61K49/0002 , C07K14/52 , C07K14/705 , C12Y204/02036
Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
-
公开(公告)号：US20180155437A1
公开(公告)日：2018-06-07
申请号：US15835566
申请日：2017-12-08
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Denise Mazess Herpai
Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
-
公开(公告)号：US20160297863A1
公开(公告)日：2016-10-13
申请号：US15035560
申请日：2014-11-11
Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： Waldemar Debinski , Carla Lema Tome , Sara Ferluga , Poonam S. Sonawane
IPC: C07K14/705 , G01N33/574 , C07K14/54
CPC classification number: C07K14/705 , A61K38/00 , C07K14/52 , C07K14/5437 , C07K2319/01 , C07K2319/06 , C07K2319/09 , C07K2319/30 , C07K2319/33 , C07K2319/55 , C07K2319/74 , G01N33/57492
Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Rα2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
Abstract translation: 本文提供了包含组合的EphA3，EphA2和/或EphB2结合配体的构建体; 和至少一个效应分子。 在一些实施方案中，所述至少一个效应分子包含治疗剂，纳米颗粒，可检测组，脂质或脂质体。 在一些实施方案中，构建体是融合蛋白和/或共价缀合物。 还提供了包含组合的构建体：结合EphA2，EphA3和/或EphB2的配体; 与IL-13Rα2结合的配体; 和至少一个效应分子。 还提供了其用于治疗癌症的方法。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.03 seconds)
